drugset / Trial / NCT02006706
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment. All patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and methotrexate (10-25mg po) weekly. The anticipated time on study treatment is 3-12 months.
Timeline
- Start
- 2006-08-10
- Primary completion
- 2007-11-23
- Completion
- 2007-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 10 mg | Oral |
| Subject | Methotrexate | Small molecule | 25 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |